^Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program
doi: 10.2106/JBJS.CC.17.00133
Current State of Research Scientific literature on GHK-Cu includes extensive preclinical investigation across dermatological, connective tissue, and cellular biology models
Ung vin ny ng ngon gic, m da d thay i, trng hng khe mnh, vt thm m i r rt
doi: 10.3390/nu10111564
Referral to hepatology should be considered for persistent unexplained LFT elevation 6 months, high FIB-4 score, abnormal elastography/imaging, or signs of clinical decompensation